Aquestive Therapeutics (AQST) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harrow (HROW) has outperformed Aquestive Therapeutics (AQST) over the past year, losing 23.2% versus a loss of 23.2%. Over five years, HROW leads with a +208.6% price change compared with +23.0% for AQST. Harrow is the larger company by market cap ($1.14 billion vs $597.4 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | HROW |
|---|---|---|
| Share price | $4.76 | $30.52 |
| Market cap | $597.44M | $1.14B |
| 1-day change | +3.03% | -0.33% |
| YTD return | -26.32% | -37.71% |
| 1-year return | -23.23% | -23.20% |
| 5-year return | +23.00% | +208.59% |
| Forward P/E | — | 11.01 |
| EPS (TTM) | $-0.66 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $54.85 |
| 52-week low | $2.93 | $28.54 |
| Distance from 52-week high | -36.95% | -44.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +96.01% | +112.98% |
| Average volume | 2.68M | 555.55K |
| Shares outstanding | 125.51M | 37.49M |
| Employees | 147 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
AQST vs HROW FAQ
Which is bigger, Aquestive Therapeutics or Harrow?
Harrow (HROW) is larger, with a market capitalization of $1.14B compared with $597.44M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or HROW?
HROW returned -23.20% over the past 12 months, compared with -23.23% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.